Alkermes to present narcolepsy drug data at neurology meeting

April 16, 2026 7:00 AM

Alkermes plc (NASDAQ: ALKS) announced it will present additional data from its Vibrance-1 phase 2 study of alixorexton for narcolepsy ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found